RU2726625C2 - Фармацевтическая композиция, включающая полипептид - Google Patents

Фармацевтическая композиция, включающая полипептид Download PDF

Info

Publication number
RU2726625C2
RU2726625C2 RU2017134594A RU2017134594A RU2726625C2 RU 2726625 C2 RU2726625 C2 RU 2726625C2 RU 2017134594 A RU2017134594 A RU 2017134594A RU 2017134594 A RU2017134594 A RU 2017134594A RU 2726625 C2 RU2726625 C2 RU 2726625C2
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
polypeptide
ala
glycofurol
dimethylsulphoxide
Prior art date
Application number
RU2017134594A
Other languages
English (en)
Other versions
RU2017134594A3 (ru
RU2017134594A (ru
Inventor
Тацуя МИЯДЗАКИ
Кендзи МАСАКИ
Комеи ОКАБЕ
Кадзухито Ямада
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд. filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of RU2017134594A publication Critical patent/RU2017134594A/ru
Publication of RU2017134594A3 publication Critical patent/RU2017134594A3/ru
Application granted granted Critical
Publication of RU2726625C2 publication Critical patent/RU2726625C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/08—Polyethers derived from hydroxy compounds or from their metallic derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к фармацевтической композиции, включающей лекарственное средство и полипептид, представленный Ac-(Arg-Ala-Asp-Ala)-NH, и дополнительно содержащая органический растворитель, выбранный из группы, состоящей из полиэтиленгликоля, диметилсульфоксида, гликофурола и N-метилпирролидона. Фармацевтическая композиция пролонгированно высвобождает лекарственное средство в организме. 3 н. и 12 з.п. ф-лы, 4 табл., 4 пр.
RU2017134594A 2015-03-17 2016-03-16 Фармацевтическая композиция, включающая полипептид RU2726625C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015053757 2015-03-17
JP2015-053757 2015-03-17
PCT/JP2016/058359 WO2016148201A1 (ja) 2015-03-17 2016-03-16 ポリペプチドを含有する医薬組成物

Publications (3)

Publication Number Publication Date
RU2017134594A RU2017134594A (ru) 2019-04-05
RU2017134594A3 RU2017134594A3 (ru) 2019-08-23
RU2726625C2 true RU2726625C2 (ru) 2020-07-15

Family

ID=56919060

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134594A RU2726625C2 (ru) 2015-03-17 2016-03-16 Фармацевтическая композиция, включающая полипептид

Country Status (11)

Country Link
US (1) US9987368B2 (ru)
EP (1) EP3272360B1 (ru)
JP (1) JP6709088B2 (ru)
KR (1) KR102538806B1 (ru)
CN (1) CN108064171B (ru)
CA (1) CA2979802C (ru)
ES (1) ES2935917T3 (ru)
HK (2) HK1243347A1 (ru)
RU (1) RU2726625C2 (ru)
TW (1) TWI677346B (ru)
WO (1) WO2016148201A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721255B (zh) * 2017-05-10 2021-03-11 大陸商思路迪（北京）醫藥科技有限公司 一種具有抗癌作用的化合物及其製備方法和應用（一）

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149574A1 (en) * 2004-02-17 2007-06-28 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
WO2013126017A1 (en) * 2012-02-22 2013-08-29 Agency For Science, Technology And Research Organogels and emulsions for biological and non-biological applications
RU2517117C2 (ru) * 2012-11-26 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций
WO2014133027A1 (ja) * 2013-02-26 2014-09-04 株式会社スリー・ディー・マトリックス ハイドロゲル

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
CA2767992C (en) * 2009-07-17 2017-03-21 Santen Pharmaceutical Co., Ltd. 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
JP5732691B2 (ja) 2010-01-14 2015-06-10 学校法人同志社 インスリン製剤
WO2014120886A1 (en) * 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
JP5856264B2 (ja) * 2013-09-20 2016-02-09 参天製薬株式会社 ポリエチレングリコール含有組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149574A1 (en) * 2004-02-17 2007-06-28 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
WO2013126017A1 (en) * 2012-02-22 2013-08-29 Agency For Science, Technology And Research Organogels and emulsions for biological and non-biological applications
RU2517117C2 (ru) * 2012-11-26 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций
WO2014133027A1 (ja) * 2013-02-26 2014-09-04 株式会社スリー・ディー・マトリックス ハイドロゲル

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B BRIUGLIA, MARIA-LUCIA et al., "Sustained and controlled release of lipophilic drugs from a self-assembling amphiphilic peptide hydrogel", International Journal of Pharmaceutics, 2014, vol. 474, no. 1, pages 103 - 111. *
XU X-D ET AL, "Peptide hydrogel as an intraocular drug delivery system for inhibition of postoperative scarring formation", ACS APPLIED MATERIALS AND INTERFACES 2010, 2010, vol. 2, no. 9, pages 2663 - 2671. *

Also Published As

Publication number Publication date
HK1255586A1 (zh) 2019-08-23
ES2935917T3 (es) 2023-03-13
CA2979802C (en) 2023-06-27
HK1243347A1 (zh) 2018-07-13
EP3272360B1 (en) 2022-11-23
WO2016148201A1 (ja) 2016-09-22
US9987368B2 (en) 2018-06-05
EP3272360A4 (en) 2018-05-02
KR102538806B1 (ko) 2023-05-31
CN108064171A (zh) 2018-05-22
RU2017134594A3 (ru) 2019-08-23
JP6709088B2 (ja) 2020-06-10
CN108064171B (zh) 2021-07-13
TW201639589A (zh) 2016-11-16
RU2017134594A (ru) 2019-04-05
JP2016172730A (ja) 2016-09-29
CA2979802A1 (en) 2016-09-22
TWI677346B (zh) 2019-11-21
KR20170129832A (ko) 2017-11-27
US20180064818A1 (en) 2018-03-08
EP3272360A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
PH12019500579A1 (en) Pharmaceutical composition
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
MY187047A (en) Selective pyy compounds and uses thereof
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
WO2015038533A3 (en) Sodium channel modulators for the treatment of pain and diabetes
MY191980A (en) Formulations containing an extract of echinacea and linoleic acid derivatives
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
MX2016014696A (es) Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
RU2726625C2 (ru) Фармацевтическая композиция, включающая полипептид
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
WO2019098691A3 (ko) 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법
EP2918291A3 (en) Pharmaceutical composition of stabilized paracetamol, plastic bags and use of the pharmaceutical composition
MX2017014471A (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
NZ742228A (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
MX359973B (es) Sistema farmacéutico para la administración oral de sustancias terapéuticas sensibles.